Vinpocetine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vinpocetine
Accession Number
DB12131
Type
Small Molecule
Groups
Investigational
Description

Vinpocetine has been investigated for the treatment of Epilepsy.

Structure
Thumb
Synonyms
  • CERACTIN
  • ETHYL APOVINCAMIN-22-OATE
External IDs
AY-27255
Categories
UNII
543512OBTC
CAS number
42971-09-5
Weight
Average: 350.462
Monoisotopic: 350.199428085
Chemical Formula
C22H26N2O2
InChI Key
DDNCQMVWWZOMLN-IRLDBZIGSA-N
InChI
InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
IUPAC Name
ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
SMILES
[H][[email protected]]12N3CCC[[email protected]@]1(CC)C=C(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OCC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Vinpocetine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Vinpocetine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Vinpocetine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Vinpocetine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Vinpocetine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Vinpocetine.Approved, Withdrawn
AmbrisentanVinpocetine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineVinpocetine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Vinpocetine.Approved
AmobarbitalThe metabolism of Vinpocetine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Vinpocetine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Vinpocetine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Vinpocetine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Vinpocetine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Vinpocetine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Vinpocetine.Approved
AtenololAtenolol may increase the hypotensive activities of Vinpocetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Vinpocetine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Vinpocetine.Experimental
BarbexacloneThe metabolism of Vinpocetine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Vinpocetine can be increased when combined with Barbital.Illicit
BarnidipineVinpocetine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Vinpocetine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Vinpocetine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Vinpocetine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Vinpocetine.Approved, Investigational
BepridilBepridil may increase the hypotensive activities of Vinpocetine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Vinpocetine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Vinpocetine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Vinpocetine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Vinpocetine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Vinpocetine.Approved
BosentanBosentan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Vinpocetine.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Vinpocetine.Experimental
BretyliumBretylium may increase the hypotensive activities of Vinpocetine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Vinpocetine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Vinpocetine.Experimental
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Vinpocetine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Vinpocetine.Investigational
BupranololBupranolol may increase the hypotensive activities of Vinpocetine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Vinpocetine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Vinpocetine.Approved
CadralazineCadralazine may increase the hypotensive activities of Vinpocetine.Experimental
CafedrineVinpocetine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanVinpocetine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Vinpocetine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Vinpocetine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Vinpocetine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Vinpocetine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Vinpocetine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Vinpocetine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Vinpocetine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
CaseinThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Vinpocetine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Vinpocetine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Vinpocetine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Vinpocetine.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Vinpocetine.Approved
CicletanineVinpocetine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Vinpocetine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Vinpocetine.Approved
CimetidineThe serum concentration of Vinpocetine can be increased when it is combined with Cimetidine.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Vinpocetine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Vinpocetine.Approved
CloranololVinpocetine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Vinpocetine.Approved, Vet Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Vinpocetine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Vinpocetine.Approved
CyclopenthiazideVinpocetine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Vinpocetine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Vinpocetine.Approved, Investigational
DelaprilVinpocetine may increase the hypotensive activities of Delapril.Experimental
DeserpidineVinpocetine may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Vinpocetine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Vinpocetine.Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Vinpocetine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Vinpocetine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Vinpocetine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Vinpocetine.Approved
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Vinpocetine.Approved, Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Vinpocetine.Approved
EfavirenzThe serum concentration of Vinpocetine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Vinpocetine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Vinpocetine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Vinpocetine.Approved
EndralazineEndralazine may increase the hypotensive activities of Vinpocetine.Experimental
EpanololVinpocetine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Vinpocetine.Approved
EprosartanEprosartan may increase the hypotensive activities of Vinpocetine.Approved
FelodipineFelodipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Vinpocetine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Vinpocetine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Vinpocetine.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Vinpocetine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Vinpocetine.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Vinpocetine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Vinpocetine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Vinpocetine.Approved, Investigational, Vet Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Vinpocetine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Vinpocetine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Vinpocetine.Approved
GuanazodineVinpocetine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Vinpocetine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
GuanoclorVinpocetine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzVinpocetine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanVinpocetine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Vinpocetine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Vinpocetine.Approved, Withdrawn
HarmalineHarmaline may increase the hypotensive activities of Vinpocetine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Vinpocetine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Vinpocetine.Approved, Investigational
HexobarbitalThe metabolism of Vinpocetine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Vinpocetine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Vinpocetine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Vinpocetine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Vinpocetine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Vinpocetine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Vinpocetine.Investigational
IndapamideIndapamide may increase the hypotensive activities of Vinpocetine.Approved
IndenololIndenolol may increase the hypotensive activities of Vinpocetine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Vinpocetine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Vinpocetine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Vinpocetine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Vinpocetine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Vinpocetine.Approved
IsradipineIsradipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Vinpocetine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Vinpocetine.Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Vinpocetine.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Vinpocetine.Approved
LacidipineLacidipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Vinpocetine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
LinsidomineVinpocetine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Vinpocetine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Vinpocetine.Approved
MacitentanVinpocetine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium Hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Vinpocetine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MefloquineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mefloquine.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Vinpocetine.Experimental
MethohexitalThe metabolism of Vinpocetine can be increased when combined with Methohexital.Approved
MethoserpidineVinpocetine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Vinpocetine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Vinpocetine.Approved, Investigational
MethylphenobarbitalThe metabolism of Vinpocetine can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Vinpocetine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Vinpocetine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MetyrosineVinpocetine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Vinpocetine.Experimental
MianserinThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilMibefradil may increase the hypotensive activities of Vinpocetine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Vinpocetine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Vinpocetine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Vinpocetine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Vinpocetine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Vinpocetine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Vinpocetine.Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
MuzolimineVinpocetine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Vinpocetine.Experimental
NadololNadolol may increase the hypotensive activities of Vinpocetine.Approved
NafcillinThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Vinpocetine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Vinpocetine.Investigational
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Vinpocetine.Approved
NebivololNebivolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Vinpocetine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Vinpocetine.Experimental
NiguldipineNiguldipine may increase the hypotensive activities of Vinpocetine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Vinpocetine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Vinpocetine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
NitroprussideVinpocetine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Vinpocetine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Vinpocetine.Approved, Vet Approved
ObinutuzumabVinpocetine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Vinpocetine.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Vinpocetine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Vinpocetine.Experimental
OrlistatThe serum concentration of Vinpocetine can be decreased when it is combined with Orlistat.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Vinpocetine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Vinpocetine.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Vinpocetine.Investigational
PargylinePargyline may increase the hypotensive activities of Vinpocetine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Vinpocetine.Approved, Investigational
PentobarbitalThe metabolism of Vinpocetine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Vinpocetine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Vinpocetine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Vinpocetine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Vinpocetine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Vinpocetine.Withdrawn
PhenobarbitalThe metabolism of Vinpocetine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Vinpocetine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Vinpocetine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Vinpocetine.Approved
PinacidilPinacidil may increase the hypotensive activities of Vinpocetine.Approved
PindololPindolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Vinpocetine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Vinpocetine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Vinpocetine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Vinpocetine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Vinpocetine.Approved
PregabalinThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Vinpocetine can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Vinpocetine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Vinpocetine.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Vinpocetine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Vinpocetine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Vinpocetine.Experimental
RamiprilRamipril may increase the hypotensive activities of Vinpocetine.Approved
RasagilineRasagiline may increase the hypotensive activities of Vinpocetine.Approved
RemikirenRemikiren may increase the hypotensive activities of Vinpocetine.Approved
RescinnamineVinpocetine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Vinpocetine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Vinpocetine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Vinpocetine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Vinpocetine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
RiociguatVinpocetine may increase the hypotensive activities of Riociguat.Approved
RituximabVinpocetine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Vinpocetine.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Vinpocetine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Vinpocetine.Experimental
SecobarbitalThe metabolism of Vinpocetine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Vinpocetine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Vinpocetine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Vinpocetine.Approved, Investigational
SildenafilSildenafil may increase the antihypertensive activities of Vinpocetine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Vinpocetine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Vinpocetine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Vinpocetine.Approved, Investigational
SitaxentanVinpocetine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Vinpocetine.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Vinpocetine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Vinpocetine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Vinpocetine.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Vinpocetine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Vinpocetine.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Vinpocetine.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Vinpocetine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Vinpocetine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Vinpocetine.Investigational
TheodrenalineVinpocetine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Vinpocetine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Vinpocetine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Vinpocetine.Approved
TiboloneTibolone may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Vinpocetine.Withdrawn
TimololTimolol may increase the hypotensive activities of Vinpocetine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Vinpocetine.Approved
TolazolineTolazoline may increase the hypotensive activities of Vinpocetine.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Vinpocetine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Vinpocetine.Approved, Investigational, Vet Approved
TolonidineVinpocetine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Vinpocetine.Approved
TorasemideTorasemide may increase the hypotensive activities of Vinpocetine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Vinpocetine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Vinpocetine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Vinpocetine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Vinpocetine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Vinpocetine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Vinpocetine.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Vinpocetine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Vinpocetine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Vinpocetine.Investigational
ValsartanValsartan may increase the hypotensive activities of Vinpocetine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Vinpocetine.Approved
VincamineVinpocetine may increase the hypotensive activities of Vincamine.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Vinpocetine.Approved, Investigational
XipamideVinpocetine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Vinpocetine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Vinpocetine.Approved, Investigational, Vet Approved
ZofenoprilVinpocetine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
443955
PubChem Substance
347828430
ChemSpider
392007
BindingDB
50059033
ChEBI
32297
ChEMBL
CHEMBL71752
ATC Codes
N06BX18 — Vinpocetine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentEpilepsies1
2, 3CompletedTreatmentImmunoregulation / Inflammatory Reaction / Strokes / Vinpocetine1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0254 mg/mLALOGPS
logP4.35ALOGPS
logP4.07ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)6.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity104.24 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fsi-1292000000-d2a82dd6f1fdac32445e

Taxonomy

Description
This compound belongs to the class of organic compounds known as eburnan-type alkaloids. These are alkaloids with a structure based on the eburnan skeleton, that arises from rearrangement of the aspidospermidine ring system, involving migration of C-21 from C-7 to C-2, fission of the 2,16-bond, and attachment of C-16 to N-1.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Eburnan-type alkaloids
Sub Class
Not Available
Direct Parent
Eburnan-type alkaloids
Alternative Parents
Indolonaphthyridine alkaloids / Beta carbolines / 3-alkylindoles / Alpha amino acids and derivatives / Naphthyridines / Aralkylamines / Piperidines / Benzenoids / Pyrroles / Heteroaromatic compounds
show 8 more
Substituents
Eburna alkaloid / Indolo[3,2-1de][1,5]naphthyridine / Beta-carboline / Pyridoindole / Diazanaphthalene / Alpha-amino acid or derivatives / Naphthyridine / 3-alkylindole / Indole / Indole or derivatives
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:24 / Updated on December 01, 2017 16:27